MA44922B1 - Anticorps - Google Patents
AnticorpsInfo
- Publication number
- MA44922B1 MA44922B1 MA44922A MA44922A MA44922B1 MA 44922 B1 MA44922 B1 MA 44922B1 MA 44922 A MA44922 A MA 44922A MA 44922 A MA44922 A MA 44922A MA 44922 B1 MA44922 B1 MA 44922B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibody
- binding
- fragment
- present
- dna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Abstract
La présente invention concerne un anticorps anti-csf-1r et des fragments de liaison associés, de l'adn codant pour celui-ci, des cellules hôtes comportant ledit adn et des méthodes d'expression de l'anticorps ou d'un fragment de liaison dans une cellule hôte. La présente invention s'étend également à des compositions pharmaceutiques comprenant l'anticorps ou un fragment de liaison associé, et l'utilisation de l'anticorps, du fragment de liaison et des compositions les comprenant dans un traitement.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1315487.7A GB201315487D0 (en) | 2013-08-30 | 2013-08-30 | Antibodies |
PCT/EP2014/068050 WO2015028455A1 (fr) | 2013-08-30 | 2014-08-26 | Anticorps |
Publications (2)
Publication Number | Publication Date |
---|---|
MA44922A1 MA44922A1 (fr) | 2019-08-30 |
MA44922B1 true MA44922B1 (fr) | 2020-06-30 |
Family
ID=49397073
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38930A MA38930A1 (fr) | 2013-08-30 | 2014-08-26 | Anticorps, anti-récépteur du facteur de stimulation des colonies (csf1r) |
MA44922A MA44922B1 (fr) | 2013-08-30 | 2014-08-26 | Anticorps |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38930A MA38930A1 (fr) | 2013-08-30 | 2014-08-26 | Anticorps, anti-récépteur du facteur de stimulation des colonies (csf1r) |
Country Status (39)
Country | Link |
---|---|
US (2) | US9908939B2 (fr) |
EP (3) | EP3549599B1 (fr) |
JP (3) | JP6632075B2 (fr) |
KR (1) | KR102303130B1 (fr) |
CN (2) | CN105658236B (fr) |
AR (1) | AR097464A1 (fr) |
AU (1) | AU2014314304B2 (fr) |
BR (1) | BR112016004324B1 (fr) |
CA (1) | CA2922240C (fr) |
CL (1) | CL2016000438A1 (fr) |
CY (1) | CY1121964T1 (fr) |
DK (2) | DK3038643T3 (fr) |
EA (1) | EA036255B1 (fr) |
ES (2) | ES2733735T3 (fr) |
FI (1) | FI3549599T3 (fr) |
GB (1) | GB201315487D0 (fr) |
HK (1) | HK1220142A1 (fr) |
HR (2) | HRP20231264T1 (fr) |
HU (2) | HUE045672T2 (fr) |
IL (1) | IL244043B (fr) |
LT (2) | LT3549599T (fr) |
MA (2) | MA38930A1 (fr) |
MX (1) | MX2016002166A (fr) |
MY (1) | MY172484A (fr) |
NZ (1) | NZ717399A (fr) |
PE (2) | PE20201067A1 (fr) |
PH (1) | PH12016500275A1 (fr) |
PL (2) | PL3549599T3 (fr) |
PT (2) | PT3549599T (fr) |
RS (2) | RS64784B1 (fr) |
SG (1) | SG11201601151PA (fr) |
SI (2) | SI3549599T1 (fr) |
TN (1) | TN2016000067A1 (fr) |
TR (1) | TR201909478T4 (fr) |
TW (1) | TWI531582B (fr) |
UA (1) | UA118354C2 (fr) |
UY (1) | UY35718A (fr) |
WO (1) | WO2015028455A1 (fr) |
ZA (1) | ZA201601437B (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201315487D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
US10316097B2 (en) * | 2015-05-27 | 2019-06-11 | Ucb Biopharma Sprl | Method for the treatment of epilepsy, epileptogenesis, seizures or convulsions by an anti-colony-stimulating factor 1 receptor (CSF-1R) antibody |
EP3302552A1 (fr) * | 2015-06-02 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Compositions et méthodes d'utilisation d'anticorps anti-il -34 pour traiter des maladies neurologiques |
CA3026477A1 (fr) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anticorps |
WO2018183366A1 (fr) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Polythérapies d'anticorps csf-1r ou csf-1 et thérapie reposant sur des lymphocytes t |
CN111278459A (zh) * | 2017-05-19 | 2020-06-12 | 赛达克斯制药股份有限公司 | 组合疗法 |
GB201803226D0 (en) | 2018-02-28 | 2018-04-11 | Ultrahuman Twelve Ltd | CSF1R Binding agents |
CN109096397B (zh) * | 2018-07-18 | 2019-04-16 | 博奥信生物技术(南京)有限公司 | 一种抗人csf-1r单克隆抗体及应用 |
CN108948198B (zh) * | 2018-07-18 | 2020-09-01 | 博奥信生物技术(南京)有限公司 | 抗人csf-1r单克隆抗体及其应用 |
CN113301960A (zh) * | 2018-12-13 | 2021-08-24 | 财团法人生物技术开发中心 | 抗人类csf-1r抗体和其用途 |
WO2020232051A1 (fr) * | 2019-05-15 | 2020-11-19 | Biosion Inc. | Anticorps se liant à csf-1r et son utilisation |
CN114835811B (zh) * | 2019-12-24 | 2024-03-26 | 宝船生物医药科技(上海)有限公司 | 抗csf1r分子及其用途 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
CA2090126C (fr) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methodes de production de proteines dotees d'une fonction desiree |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
EP1570267B1 (fr) | 2002-12-03 | 2011-10-12 | UCB Pharma, S.A. | Dosage biologique permettant d'identifier des cellules productrices d'anticorps |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
US7989594B2 (en) | 2003-07-01 | 2011-08-02 | Celltech R & D Limited | Modified antibody fab fragments |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
WO2005014655A2 (fr) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugues d'amidon d'hydroxyalkyle et de proteine |
AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
MY146381A (en) * | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
EP2188313B1 (fr) * | 2007-08-21 | 2017-11-01 | Amgen, Inc. | Proteines de liaison a un antigene de c-fms humain |
EP2195341B1 (fr) | 2007-09-26 | 2017-03-22 | UCB Biopharma SPRL | Fusions d'anticorps à double spécificité |
JO3240B1 (ar) * | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
NZ587830A (en) * | 2008-03-14 | 2012-08-31 | Transgene Sa | Antibody against the colony-stimulating factor-1 receptor (CSF-1R) |
US8470977B2 (en) * | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
SI2334705T1 (sl) | 2008-09-26 | 2017-05-31 | Ucb Biopharma Sprl | Biološki produkti |
ES2667258T3 (es) | 2009-09-10 | 2018-05-10 | Ucb Biopharma Sprl | Anticuerpos multivalentes |
GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
CN102791738B (zh) * | 2009-12-10 | 2015-10-07 | 霍夫曼-拉罗奇有限公司 | 优先结合人csf1r胞外域4的抗体及其用途 |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
BR112012020372A8 (pt) * | 2010-03-05 | 2018-01-02 | Hoffmann La Roche | anticorpo que se liga ao csf-1r humano, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira e método para a produção de um anticorpo recombinante |
MX336682B (es) * | 2010-03-05 | 2016-01-27 | Hoffmann La Roche | Anticuerpos contra csf-1r humanos y usos de los mismos. |
AR080698A1 (es) * | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
LT2566517T (lt) * | 2010-05-04 | 2019-01-10 | Five Prime Therapeutics, Inc. | Antikūnai, surišantys csf1r |
CN104159921B (zh) * | 2011-12-15 | 2018-05-04 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
GB201315486D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
GB201315487D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
-
2013
- 2013-08-30 GB GBGB1315487.7A patent/GB201315487D0/en not_active Ceased
-
2014
- 2014-08-05 TW TW103126815A patent/TWI531582B/zh active
- 2014-08-26 AU AU2014314304A patent/AU2014314304B2/en active Active
- 2014-08-26 FI FIEP19171833.7T patent/FI3549599T3/fi active
- 2014-08-26 LT LTEP19171833.7T patent/LT3549599T/lt unknown
- 2014-08-26 MX MX2016002166A patent/MX2016002166A/es active IP Right Grant
- 2014-08-26 WO PCT/EP2014/068050 patent/WO2015028455A1/fr active Application Filing
- 2014-08-26 TN TN2016000067A patent/TN2016000067A1/en unknown
- 2014-08-26 MA MA38930A patent/MA38930A1/fr unknown
- 2014-08-26 EP EP19171833.7A patent/EP3549599B1/fr active Active
- 2014-08-26 PE PE2020000532A patent/PE20201067A1/es unknown
- 2014-08-26 UA UAA201601175A patent/UA118354C2/uk unknown
- 2014-08-26 EP EP14755668.2A patent/EP3038643B1/fr active Active
- 2014-08-26 SI SI201432048T patent/SI3549599T1/sl unknown
- 2014-08-26 CN CN201480057403.8A patent/CN105658236B/zh active Active
- 2014-08-26 PT PT191718337T patent/PT3549599T/pt unknown
- 2014-08-26 KR KR1020167007073A patent/KR102303130B1/ko active IP Right Grant
- 2014-08-26 MA MA44922A patent/MA44922B1/fr unknown
- 2014-08-26 DK DK14755668.2T patent/DK3038643T3/da active
- 2014-08-26 PE PE2016000313A patent/PE20160528A1/es unknown
- 2014-08-26 HU HUE14755668A patent/HUE045672T2/hu unknown
- 2014-08-26 HR HRP20231264TT patent/HRP20231264T1/hr unknown
- 2014-08-26 JP JP2016537262A patent/JP6632075B2/ja active Active
- 2014-08-26 RS RS20230962A patent/RS64784B1/sr unknown
- 2014-08-26 LT LTEP14755668.2T patent/LT3038643T/lt unknown
- 2014-08-26 MY MYPI2016700624A patent/MY172484A/en unknown
- 2014-08-26 RS RS20190833A patent/RS59019B1/sr unknown
- 2014-08-26 HU HUE19171833A patent/HUE064437T2/hu unknown
- 2014-08-26 SG SG11201601151PA patent/SG11201601151PA/en unknown
- 2014-08-26 ES ES14755668T patent/ES2733735T3/es active Active
- 2014-08-26 PL PL19171833.7T patent/PL3549599T3/pl unknown
- 2014-08-26 NZ NZ717399A patent/NZ717399A/en unknown
- 2014-08-26 BR BR112016004324-3A patent/BR112016004324B1/pt active IP Right Grant
- 2014-08-26 SI SI201431235T patent/SI3038643T1/sl unknown
- 2014-08-26 PT PT14755668T patent/PT3038643T/pt unknown
- 2014-08-26 EP EP23192221.2A patent/EP4282881A3/fr active Pending
- 2014-08-26 EA EA201690503A patent/EA036255B1/ru not_active IP Right Cessation
- 2014-08-26 US US14/914,676 patent/US9908939B2/en active Active
- 2014-08-26 ES ES19171833T patent/ES2965207T3/es active Active
- 2014-08-26 TR TR2019/09478T patent/TR201909478T4/tr unknown
- 2014-08-26 DK DK19171833.7T patent/DK3549599T3/da active
- 2014-08-26 PL PL14755668T patent/PL3038643T3/pl unknown
- 2014-08-26 CA CA2922240A patent/CA2922240C/fr active Active
- 2014-08-26 CN CN202011009068.8A patent/CN112321711A/zh active Pending
- 2014-08-27 AR ARP140103206A patent/AR097464A1/es unknown
- 2014-08-29 UY UY35718A patent/UY35718A/es not_active Application Discontinuation
-
2016
- 2016-02-09 IL IL244043A patent/IL244043B/en active IP Right Grant
- 2016-02-10 PH PH12016500275A patent/PH12016500275A1/en unknown
- 2016-02-25 CL CL2016000438A patent/CL2016000438A1/es unknown
- 2016-03-02 ZA ZA2016/01437A patent/ZA201601437B/en unknown
- 2016-07-15 HK HK16108335.9A patent/HK1220142A1/zh unknown
-
2018
- 2018-01-30 US US15/883,130 patent/US10421814B2/en active Active
-
2019
- 2019-06-12 HR HRP20191051TT patent/HRP20191051T1/hr unknown
- 2019-07-23 CY CY20191100779T patent/CY1121964T1/el unknown
- 2019-09-13 JP JP2019166697A patent/JP7195237B2/ja active Active
-
2021
- 2021-09-17 JP JP2021152574A patent/JP2022002523A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA44922B1 (fr) | Anticorps | |
SG10201907215QA (en) | Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof | |
BR112020002012A8 (pt) | Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39 | |
MA39096B1 (fr) | Anticorps spécifiques à fcrn | |
ATE516814T1 (de) | 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese | |
MA32948B1 (fr) | Anticorps anti-pd-l1 et leur utilisation pour ameliorer la fonction des lymphocytes t | |
MA38308A1 (fr) | Molécules de liaison à l'antigène bispécifiques activant des lymphocytes t | |
MA40609B1 (fr) | Agents de liaison cd123 et leurs utilisations | |
EA201892774A1 (ru) | Антитела | |
EA202092589A3 (ru) | Cxcr2-связывающие полипептиды | |
TR201910103T4 (tr) | Anti-fcrn antikorları. | |
MA38478A1 (fr) | Anticorps anti-pac1 humains | |
EA201270761A1 (ru) | Белки на основе структурного домена фибронектина, связывающие pcsk9 | |
JO3623B1 (ar) | البروتينات المرتبطة بمولد المستضاد st2 | |
MA37407B1 (fr) | Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine | |
EA201000424A1 (ru) | Антитела к il-23 | |
EA201590247A1 (ru) | Антитела к siglec-15 | |
PH12019500571A1 (en) | Anti-pd-1 antibodies | |
EA201492048A1 (ru) | Полипептиды, связывающиеся с хемокиновым рецептором | |
MA44593B1 (fr) | Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations | |
EA201400964A1 (ru) | Cx3cr1-связывающие полипептиды | |
IN2014CN04645A (fr) | ||
MX2018000447A (es) | Novedosas proteinas especificas para lag-3. | |
MX2015014198A (es) | Anticuerpos cuyo objetivo es m-csf. | |
MX2016001193A (es) | Medicamento que comprende anticuerpo anti-fosfolipasa d4. |